HeartBeam Appoints Robert Eno as CEO, Focused on U.S. Commercialization
Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and driving growth
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company dedicated to transforming cardiac care, has announced the appointment of Robert Eno as Chief Executive Officer (CEO), effective October 21, 2024. Eno, who joined the company as President in January 2023, will guide HeartBeam as it seeks FDA 510(k) clearance for its innovative vector-based technology and prepares for commercialization.
As part of this transition, Branislav Vajdic, Ph.D., the founder and current CEO, will assume the role of President, focusing on advancing the company’s pioneering vector-based technology and enhancing artificial intelligence (AI) applications.
“HeartBeam is at a crucial juncture, and this leadership transition allows us to leverage the unique strengths of each leader effectively. Branislav’s commitment to innovation and vision for unprecedented cardiac insights has brought us to this pivotal moment, and we will continue to benefit from his dedication to unlocking transformative opportunities. Rob’s extensive experience in growing innovative technology companies through strategic marketing and go-to-market strategies will position us for success,” said Rich Ferrari, Executive Chairman of the Board of Directors at HeartBeam.
HeartBeam’s core technology captures the heart’s electrical signals in three dimensions, providing comprehensive cardiac intelligence. The company’s first application is a cable-free, credit card-sized device capable of synthesizing a 12-lead ECG, currently under FDA review. HeartBeam holds 13 U.S. patents and 4 international patents related to its technology.
“The HeartBeam technology is revolutionary and has the potential to transform cardiac care management. We are just beginning to uncover new insights from our data-rich signals that can benefit both physicians and patients,” said Eno. “I am honored to lead the company at this exciting time and look forward to collaborating with Branislav as we evolve our business and technology to meet our strategic objectives.”
With over 30 years of experience, Eno has developed go-to-market strategies for several breakthrough products, including noninvasive FFRCT for coronary artery disease diagnosis and laser cataract surgery. Before joining HeartBeam, he served as CEO of Preview Medical, which focused on real-time tissue classification for solid tumor cancers using machine learning. Eno has also held senior marketing and sales roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular. He earned an MBA from the Stanford Graduate School of Business and holds a BA with honors and distinction from Stanford University, where he was Phi Beta Kappa.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.
